Molnupiravir para el tratamiento de pacientes con COVID-19
https://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.1354072
Eficacia, seguridad y recomendaciones de uso de vacunas contra el virus del papiloma humano (VPH) en niños expuestos e infectados por virus de inmunodeficiencia humana (VIH)
https://sites.bvsalud.org/redetsa/brisa/resource/?id=biblioref.referencesource.1354025
🚨 "As #COVID19 cases are spreading more actively – and more quickly – than ever before, it’s clear that omicron has become the predominant SARS-CoV-2 strain 🦠 in our region 🌎 at the moment", @DirOPSPAHO https://t.co/aH69nzC9yU
As the #COVID19 outbreak reaches its third year in the Americas 🌎, millions of children are missing out on routine vaccinations, putting countries at risk of losing two decades of immunization progress.
And last week, the WHO’s expert group on immunization authorized Pfizer’s COVID vaccine for children between the ages of 5 and 11, offering a roadmap for countries that may be ready to roll out COVID vaccines for them.
Countries must act urgently so the next generation has the health, education, and social opportunities to reach their fullest potential and so that no child or teen is left behind.
This data holds the key for how to restore or offer these services safely.
As countries weigh the benefits of vaccinating children, and as they work to bring back in-person learning, I want to reinforce a point I made at the top: the need for better and more granular data.
